Thursday - October 29, 2026
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study
October 28, 2026
BUFFALO, New York, Oct. 28 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:

* * *

Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study

*

Clinical trial assessing bevacizumab-pazopanib combination focused on patients with untreated metastatic disease

* Landmark study extended both progression-free and overall survival

. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products